Gregory A. Daniels

Career Trajectory

Research Cluster Map

Direct collaborators. Node size = influence, colour = community, dashed = past collaboration.

• Ultrasensitive ctDNA monitoring reveals early predictors of immunotherapy response in advanced cancer

  npj Precision Oncology · 2026-01-24 · 3 citations

• A phase Ib/II study of modakafusp alfa alone and in combination with pembrolizumab in patients with advanced or metastatic solid tumors

  Frontiers in Oncology · 2025-12-08

• 604 Phase 2 study of neoadjuvant nivolumab + relatlimab versus nivolumab in patients with resectable high-risk basal cell carcinoma

  Regular and Young Investigator Award Abstracts · 2025-11-01

• Supplementary Table S1 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

  2025-10-01

• Supplementary Figure S4 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

  2025-10-01

• Data from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

  2025-10-01

• Supplementary Figure S3 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

  2025-10-01

• Supplementary Table S3 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

  2025-10-01

• Supplementary Table S2 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

  2025-10-01

• Supplementary Figure S2 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

  2025-10-01

• Supplementary Figure S5 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

  2025-10-01

• Supplementary Figure S1 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

  2025-10-01

• Supplementary Figure S6 from Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

  2025-10-01

• Phase 2, Open-Label, Multicenter Study of Nelitolimod in Combination with Pembrolizumab in Anti–PD-1 Treatment-Naïve Advanced Melanoma

  Clinical Cancer Research · 2025-07-25 · 5 citations

• Long-Term Efficacy and Safety of Lifileucel Tumor-Infiltrating Lymphocyte Cell Therapy in Patients With Advanced Melanoma: A 5-Year Analysis of the C-144-01 Study

  Journal of Clinical Oncology · 2025-06-02 · 34 citations

• Antigenic cancer persister cells survive direct T cell attackPreprint

  bioRxiv (Cold Spring Harbor Laboratory) · 2025-03-17 · 2 citations

• Racial Differences in Systemic Immune Parameters in Individuals With Lung Cancer

  JTO Clinical and Research Reports · 2024-10-19 · 4 citations

• Baseline biomarkers of efficacy and on-treatment immune-profile changes associated with bempegaldesleukin plus nivolumab

  npj Precision Oncology · 2024-07-18 · 5 citations